Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenesis Signs Discovery Collaboration with Amgen

NEW YORK, Aug. 4 (GenomeWeb News) - Chemical genomics firm NeoGenesis Pharmaceuticals said today that it has signed a multi-year drug discovery collaboration agreement with Amgen.

 

NeoGenesis will use its ALIS (Automated Ligand Identification System) platform along with its compound libraries and lead optimization technologies in the project, which will focus on the discovery of small-molecule drugs for cancer, neurodegenerative diseases, and inflammatory diseases.

 

The company will receive research funding, milestone payments, and royalties based on the successful development of drug candidates.

 

NeoGenesis, headquartered in Cambridge, Mass., has similar partnerships with Aventis Pharma, Biogen, Celltech, Japan Tobacco, Merck, Mitsubishi Pharma, Pfizer, Schering-Plough, and Tularik.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.